To investigate if differences in imprinting at tropho-microRNA (miRNA) genomic clusters can distinguish between pre-gestational trophoblastic neoplasia cases (pre-GTN) and benign complete hydatidiform mole (CHM) cases at the time of initial uterine evacuation. miRNA sequencing was performed on frozen tissue from 39 CHM cases including 9 GTN cases. DIO3, DLK1, RTL1, and MEG 3 mRNA levels were assessed by qRT-PCR. Protein abundance was assessed by Western blot for DIO3, DLK1, and RTL1. qRT-PCR and Western blot were performed for selenoproteins and markers of oxidative stress. Immunohistochemistry (IHC) was performed for DIO3 on an independent validation set of clinical samples (n = 42) and compared to normal placenta controls across gestational ages. Relative expression of the 14q32 miRNA cluster was lower in pre-GTN cases. There were no differences in protein abundance of DLK1 or RTL1. Notably, there was lower protein expression of DIO3 in pre-GTN cases (5-fold, p < 0.03). There were no differences in mRNA levels of DIO3, DLK1, RTL1 or MEG 3. mRNA levels were higher in all CHM cases compared to normal placenta. IHC showed syncytiotrophoblast-specific DIO3 immunostaining in benign CHM cases and normal placenta, while pre-GTN cases of CHM lacked DIO3 expression. We describe two new biomarkers of pre-GTN CHM cases: decreased 14q32 miRNA expression and loss of DIO3 expression by IHC. Differences in imprinting between benign CHM and pre-GTN cases may provide insight into the fundamental development of CHM.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s43032-021-00634-yDOI Listing

Publication Analysis

Top Keywords

chm cases
20
dlk1 rtl1
16
pre-gtn cases
16
dio3 dlk1
12
mrna levels
12
normal placenta
12
cases
11
complete hydatidiform
8
hydatidiform mole
8
trophoblastic neoplasia
8

Similar Publications

Objective: In China, Chinese herbal medicines (CHMs) have been widely used in the treatment of psoriatic arthritis (PsA), showing great therapeutic effects in clinical practice. However, due to the great heterogeneity of PsA and the diversity of CHM combination patterns, there is little high-level evidence-based medical research on the treatment of PsA with CHMs. This study aims to explore the beneficial effects of CHMs on the immune inflammation in PsA and its specific mechanism.

View Article and Find Full Text PDF

Background: Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of follicular lymphoma.

Methods: We did a single-arm, investigator-initiated, phase 2 trial at Sylvester Comprehensive Cancer Center in Miami, FL, USA.

View Article and Find Full Text PDF

A new uterine endometrium preservation hysteroscopic myomectomy: Introduction of improved procedures and a retrospective analysis of 94 cases.

Eur J Obstet Gynecol Reprod Biol X

December 2024

Department of Obstetrics and Gynecology, Maruyama Memorial General Hospital, 2-10-5, Honchou, Iwatsuki-ku, Saitama City, Saitama 339-8521, Japan.

Objective: To reduce the damage of uterine endometrium caused during hysteroscopic myomectomy (HM) for reproductive aged patients, a new uterine endometrium preservation hysteroscopic myomectomy (UEP-HM) has been developed. In this study, we introduced this technique with comparing to the conventional hysteroscopic myomectomy (C-HM).

Study Design: The data from 94 patients aged 42 or younger who underwent HM (38 cases with UEP-HM and 56 cases with C-HM) for treating single Type 1 or Type 2 submucosal leiomyoma (SL) were analysed retrospectively for comparing the characteristics of both patient and target SL.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on the long-term effects of afatinib in patients with EGFR mutant non-small cell lung cancer (NSCLC) who also had other health issues, and assessed the usefulness of monitoring circulating tumor DNA (ctDNA).
  • Conducted in the UK, the TIMELY trial involved patients receiving afatinib daily until their disease progressed or they experienced significant side effects, with blood samples analyzed every 12 weeks.
  • Results showed that while the median progression-free survival was 7.9 months, some patients experienced long-term benefits, and ctDNA testing improved the detection of EGFR mutations and was linked to better outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • The study utilized chromogenic in situ hybridization and immunohistochemistry to distinguish between partial hydatidiform mole (PHM), complete hydatidiform mole (CHM), and non-molar hydropic abortion (HA) in products of conception (POCs).
  • A retrospective analysis of 44 POCs revealed a high accuracy rate, with Kappa agreement at 95.4%, effective in diagnosing the conditions and differentiating between triploid and diploid specimens.
  • The findings suggest these methods could serve as reliable surrogate markers for chromosomal ploidy, prompting future research on fresh specimens and comparing results with other diagnostic techniques like flow cytometry and fluorescence in situ hybridization.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!